News & Events about Lexicon Pharmaceuticals Inc.
StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX Get Rating) from a sell rating to a hold rating in a research note released on Thursday. Lexicon Pharmaceuticals Stock Performance Shares of NASDAQ:LXRX opened at $2.08 on Thursday. The company has a market capitalization ...
Globe Newswire
2 months ago
THE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022: 34th Annual Piper Sandler Healthcare Conference5th Annual Evercore ISI HealthCONx ...
Globe Newswire
2 months ago
THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022. Jeff Wade, Lexiconspresident and chief financial officer, will make a ...
Globe Newswire
2 months ago
Conference Call and Webcast at 5:00pm ET on November 14, 2022,Following the Oral PresentationTHE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational drug ...
Globe Newswire
2 months ago
Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting, including evidence that: Sotagliflozin significantly reduced urine albumin-to-creatinine ratio (UACR)Sotagliflozin had favorable effects on albuminuria...